142 related articles for article (PubMed ID: 19347334)
1. Evaluation of drug-drug interactions with fesoterodine.
Malhotra B; Sachse R; Wood N
Eur J Clin Pharmacol; 2009 Jun; 65(6):551-60. PubMed ID: 19347334
[TBL] [Abstract][Full Text] [Related]
2. Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.
Malhotra B; Dickins M; Alvey C; Jumadilova Z; Li X; Duczynski G; Gandelman K
Br J Clin Pharmacol; 2011 Aug; 72(2):263-9. PubMed ID: 21545485
[TBL] [Abstract][Full Text] [Related]
3. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
[TBL] [Abstract][Full Text] [Related]
4. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
Malhotra B; Darsey E; Crownover P; Fang J; Glue P
Br J Clin Pharmacol; 2011 Aug; 72(2):226-34. PubMed ID: 21352267
[TBL] [Abstract][Full Text] [Related]
5. Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine.
Malhotra BK; Wood N; Sachse R
Int J Clin Pharmacol Ther; 2009 Sep; 47(9):570-8. PubMed ID: 19761716
[TBL] [Abstract][Full Text] [Related]
6. Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole.
Oishi M; Takano Y; Torita Y; Malhotra B; Chiba K
Drug Metab Pharmacokinet; 2018 Feb; 33(1):90-95. PubMed ID: 29338933
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic profile of fesoterodine.
Malhotra B; Guan Z; Wood N; Gandelman K
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):556-63. PubMed ID: 19000553
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations.
Oishi M; Tomono Y; Yamagami H; Malhotra B
J Clin Pharmacol; 2014 Aug; 54(8):928-36. PubMed ID: 24619889
[TBL] [Abstract][Full Text] [Related]
9. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.
Brynne N; Forslund C; Hallén B; Gustafsson LL; Bertilsson L
Br J Clin Pharmacol; 1999 Oct; 48(4):564-72. PubMed ID: 10583027
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.
Simon HU; Malhotra B
Swiss Med Wkly; 2009 Mar; 139(9-10):146-51. PubMed ID: 19145494
[TBL] [Abstract][Full Text] [Related]
11. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Malhotra B; Alvey C; Gong J; Li X; Duczynski G; Gandelman K
Br J Clin Pharmacol; 2011 Aug; 72(2):257-62. PubMed ID: 21496065
[TBL] [Abstract][Full Text] [Related]
12. Influence of food on the pharmacokinetic profile of fesoterodine.
Malhotra B; Sachse R; Wood N
Int J Clin Pharmacol Ther; 2009 Jun; 47(6):384-90. PubMed ID: 19473600
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing.
Malhotra BK; Crownover PH; LaBadie R; Glue P; MacDiarmid SA
Eur J Clin Pharmacol; 2010 Feb; 66(2):171-6. PubMed ID: 19915829
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women.
Blode H; Zeun S; Parke S; Zimmermann T; Rohde B; Mellinger U; Kunz M
Contraception; 2012 Oct; 86(4):337-44. PubMed ID: 22445438
[TBL] [Abstract][Full Text] [Related]
15. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine.
Malhotra B; Gandelman K; Sachse R; Wood N; Michel MC
Curr Med Chem; 2009; 16(33):4481-9. PubMed ID: 19835561
[TBL] [Abstract][Full Text] [Related]
16. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
18. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.
Hatorp V; Hansen KT; Thomsen MS
J Clin Pharmacol; 2003 Jun; 43(6):649-60. PubMed ID: 12817528
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
20. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
Troost J; Tatami S; Tsuda Y; Mattheus M; Mehlburger L; Wein M; Michel MC
Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
